# Borneo Kratom (Mitragyna speciosa)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/borneo-kratom
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-01
**Evidence Score:** 2 / 10
**Category:** Adaptogen
**Also Known As:** Mitragyna speciosa, Mitragyna speciosa Korth., Indonesian Kratom, Kalimantan Kratom, Biak, Ketum, Kakuam, Thom, Thang, Red Borneo, Green Borneo, White Borneo

## Overview

Borneo Kratom is a regional variety of Mitragyna speciosa whose primary bioactive alkaloids, mitragynine and 7-hydroxymitragynine, act as partial agonists at mu-opioid receptors to produce analgesia and sedation. Borneo strains are anecdotally distinguished by higher 7-hydroxymitragynine content, contributing to pronounced pain-relieving and anxiolytic effects relative to other regional varieties.

## Health Benefits

• Pain management (acute/chronic): One RCT and observational studies support analgesic effects, though evidence remains preliminary
• Opioid withdrawal symptom reduction: Cross-sectional studies report self-administered use for reducing opioid cravings and withdrawal symptoms
• Alcohol use disorder support: Observational data indicates reduced alcohol cravings, though no controlled trials exist
• Energy and fatigue management: Traditional use at low doses for work endurance, supported by user reports but lacking clinical validation
• Mood and psychiatric symptom management: Self-reported benefits in observational studies, but no randomized controlled evidence

## Mechanism of Action

Mitragynine and 7-hydroxymitragynine, the dominant alkaloids in Borneo Kratom, bind as partial agonists at mu-opioid receptors (MOR) and antagonists at delta-opioid receptors, modulating nociceptive signaling in the central nervous system. 7-hydroxymitragynine is estimated to be 13-fold more potent than morphine at MOR in vitro, and mitragynine additionally interacts with adrenergic alpha-2 receptors and [serotonin](/ingredients/condition/mood) 5-HT2A receptors, contributing to sedative and mood-modulating effects. At lower doses, dopaminergic pathway stimulation may account for reported stimulant effects, while higher doses shift the pharmacological profile toward opioid-like sedation and analgesia.

## Clinical Summary

A 2020 randomized controlled trial (n=26) evaluating kratom extract found statistically significant reductions in pain scores compared to placebo, though the study's small sample size limits generalizability. Cross-sectional survey studies involving hundreds to over 2,700 self-reported users consistently document use for chronic pain management and opioid withdrawal symptom mitigation, with respondents reporting reduced cravings and withdrawal severity. Observational data from a 2019 study (n=91) suggested kratom use was associated with reduced alcohol consumption in individuals with alcohol use disorder, though causality cannot be established. Overall, human clinical evidence remains preliminary and largely observational; no large-scale Phase III trials have been completed specifically for Borneo Kratom.

## Nutritional Profile

Borneo Kratom (Mitragyna speciosa) is not consumed as a conventional food and thus lacks a traditional macronutrient profile of significance. Its pharmacological relevance lies primarily in its alkaloid content. Key bioactive compounds include: Mitragynine (primary alkaloid, comprising approximately 60–70% of total alkaloid content in most Southeast Asian strains; typical leaf concentration ranges from 0.5–1.5% dry weight in Borneo varieties), 7-Hydroxymitragynine (minor but highly potent alkaloid, comprising <2% of total alkaloids yet exhibiting opioid receptor activity estimated 13× stronger than morphine by weight), Speciociliatine (~1% of alkaloids, partial opioid agonist activity), Speciogynine (~7% of alkaloids, weak opioid agonist), Corynantheidine (minor alkaloid with opioid antagonist properties), and Mitraphylline (oxindole alkaloid with reported immunostimulant and antihypertensive properties). Macronutrient context: crude protein content of dried leaf is approximately 8–10% dry weight (primarily structural plant proteins, not bioavailable in typical use doses of 1–8g); carbohydrates approximately 40–50% dry weight (largely cellulose and plant fiber, not metabolically significant at typical doses); fats <5% dry weight. Micronutrients present in leaf material include iron (~3–4 mg/100g dry leaf), calcium (~150 mg/100g), magnesium (~50 mg/100g), and trace amounts of zinc and potassium, though these are nutritionally negligible given typical consumption quantities (2–8g per dose). Bioavailability notes: Mitragynine is lipophilic with oral bioavailability estimated at approximately 18–24% in animal models; first-pass hepatic [metabolism](/ingredients/condition/weight-management) converts a portion of mitragynine to 7-hydroxymitragynine, which may account for some in vivo potency. Tannin content (~1–2% dry weight) may modestly impede mineral absorption when consumed as tea. No established RDA-relevant vitamin content has been documented.

## Dosage & Preparation

General kratom dosages from pharmacokinetic studies range from 1-10 g/day of leaf powder for analgesia or withdrawal management, with chronic users consuming up to 20-30 g/day. Clinical studies assessed kratom tea/extract equivalent to mitragynine 2-8 mg/kg, though no standardized Borneo-specific dosing exists. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Common adverse effects include nausea, constipation, dry mouth, tachycardia, and dose-dependent sedation; chronic high-dose use has been associated with hepatotoxicity, seizures, and physical dependence with a documented withdrawal syndrome resembling opioid withdrawal. Kratom alkaloids are metabolized via CYP3A4 and CYP2D6 enzymes, creating significant interaction risk with opioids, benzodiazepines, alcohol, and other CNS depressants, as well as drugs with narrow therapeutic windows metabolized by the same pathways. Mitragynine has demonstrated cardiotoxic potential in vitro through hERG potassium channel inhibition, raising QT-prolongation concerns when co-administered with other QT-prolonging agents. Kratom is contraindicated in pregnancy due to reports of neonatal abstinence syndrome, and it should be avoided in individuals with hepatic impairment or a history of substance use disorder without medical supervision.

## Scientific Research

Clinical evidence is limited, with a 2023 review (PMID: 37266188) identifying 18 studies (mostly cross-sectional) showing self-reported benefits for pain and substance use disorders. A 2021 systematic review (PMID: 34309900) found encouraging but preliminary evidence from 18 clinical studies for pain and withdrawal management, with only one RCT supporting analgesic effects.

## Historical & Cultural Context

Mitragyna speciosa has been used in Southeast Asian traditional medicine since at least the 19th century, with leaves chewed, brewed as tea, or smoked for energy enhancement at low doses and pain relief at higher doses. Thai, Malaysian, and Indonesian folk medicine systems have employed it for managing opioid withdrawal, diarrhea, and fatigue, though Borneo variants are not distinctly separated in historical records.

## Synergistic Combinations

Magnesium, Turmeric, Black Seed Oil, Ashwagandha, L-Theanine

## Frequently Asked Questions

### How does Borneo Kratom differ from Maeng Da or Bali Kratom?

Borneo Kratom is anecdotally reported to contain a higher ratio of 7-hydroxymitragynine to mitragynine compared to strains like Maeng Da, which is often associated with greater stimulant effects attributed to higher mitragynine concentrations. Red Vein Borneo in particular is marketed for sedation and pain relief, while Maeng Da is associated with energy and focus, though alkaloid profiles vary significantly by harvest, processing method, and vendor, and no standardized pharmacopeial definitions exist for these regional designations. Independent third-party lab analyses have confirmed meaningful alkaloid variability between commercial strains.

### Can Borneo Kratom help with opioid withdrawal?

Survey-based studies, including a widely cited 2017 cross-sectional study of 8,049 kratom users, found that approximately 68% reported using kratom to manage opioid withdrawal symptoms, citing reduced cravings, anxiety, and physical discomfort. The mechanism involves partial mu-opioid receptor agonism by mitragynine and 7-hydroxymitragynine, which may blunt withdrawal by providing sub-threshold opioid receptor stimulation. However, kratom itself carries dependence liability and is not FDA-approved for opioid use disorder; medically supervised options such as buprenorphine or methadone have substantially stronger evidence.

### What is the typical dosage of Borneo Kratom for pain relief?

Self-reported dosing data from user surveys suggest that 1–5 grams of dried Borneo Kratom leaf powder produces mild stimulant and analgesic effects, while 5–15 grams is associated with stronger opioid-like analgesia and sedation. A pharmacokinetic study found that a single 2-gram dose of kratom tea produced peak mitragynine plasma concentrations of approximately 78 ng/mL, with a half-life of roughly 9 hours. No standardized therapeutic dose has been established by any regulatory body, and dose-response relationships vary significantly based on individual CYP enzyme activity, tolerance, and product alkaloid concentration.

### Is Borneo Kratom legal in the United States?

As of 2024, Borneo Kratom and kratom products broadly remain federally legal in the United States after the DEA withdrew a proposed Schedule I classification in 2016 following public opposition. However, kratom is banned at the state level in Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin, and several municipalities have enacted local bans. The FDA has issued multiple import alerts and warning letters to kratom vendors citing adulteration and unapproved drug claims, and the agency has classified kratom as an opioid.

### Does Borneo Kratom cause liver damage?

Case reports and a 2020 systematic review identified approximately 35 documented cases of kratom-associated hepatotoxicity, presenting with a cholestatic or hepatocellular injury pattern typically appearing within 1–8 weeks of regular use. Proposed mechanisms include immune-mediated idiosyncratic reactions and direct mitragynine-induced mitochondrial dysfunction observed in in vitro hepatocyte studies. Liver injury is generally reversible upon cessation, but several cases progressed to acute liver failure; individuals with pre-existing hepatic conditions or those taking other hepatotoxic substances face substantially elevated risk.

### Does Borneo Kratom interact with medications used for depression or anxiety?

Borneo Kratom may interact with serotonergic medications (SSRIs, SNRIs) and benzodiazepines due to its alkaloid profile, though clinical studies specifically documenting these interactions are limited. Users combining Borneo Kratom with psychiatric medications should consult a healthcare provider before use. Current evidence relies primarily on theoretical mechanisms and anecdotal reports rather than controlled drug interaction trials.

### Is Borneo Kratom safe to use during pregnancy or while breastfeeding?

There is insufficient clinical evidence to determine the safety of Borneo Kratom during pregnancy or breastfeeding, and use is generally not recommended during these periods. The alkaloid composition of Borneo Kratom and potential effects on fetal development have not been adequately studied in human trials. Pregnant or breastfeeding individuals should consult with their healthcare provider before considering any kratom products.

### What does current research actually show about Borneo Kratom's effectiveness for pain?

Evidence for Borneo Kratom's pain-relief effects comes primarily from one randomized controlled trial and multiple observational studies, indicating preliminary support but not definitive proof of efficacy. Most research has small sample sizes and relies on self-reported outcomes rather than objective pain measurements. Larger, well-designed clinical trials are needed before making strong claims about its analgesic potential compared to established pain management options.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*